DUBLIN--(BUSINESS WIRE)-- <\/p>\n
Research and Markets (http:\/\/www.researchandmarkets.com\/research\/g6wsxm\/personalized<\/a>) has announced the addition of the \"Personalized Medicine Partnering Terms and Agreements\" report to their offering. <\/p>\n This report contains over 1500 links to online copies of actual personalized medicine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. <\/p>\n The initial chapters of this report provide an orientation of personalized medicine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in personalized medicine dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms. <\/p>\n Chapter 3 provides a review of the leading biomarker deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. <\/p>\n Chapter 4 provides a review of the leading companion diagnostic deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. <\/p>\n Chapter 5 provides a review of the leading pharmacogenomic deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. <\/p>\n Chapter 6 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of personalized medicine deals including biomarker, companion diagnostic, pharmacogenomics, as well as contract documents available in the public domain. <\/p>\n Chapter 7 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. <\/p>\n Chapter 8 provides a comprehensive and detailed review of companion diagnostics partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. <\/p>\n <\/p>\n Read the original: <\/p>\n Research and Markets: Recent Report on Personalized Medicine Partnering Terms and Agreements Provides a Comprehensive ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" DUBLIN--(BUSINESS WIRE)-- Research and Markets (http:\/\/www.researchandmarkets.com\/research\/g6wsxm\/personalized<\/a>) has announced the addition of the \"Personalized Medicine Partnering Terms and Agreements\" report to their offering. This report contains over 1500 links to online copies of actual personalized medicine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Continue reading